Benzinga

Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Benzinga

Premium Services
Financial News
Financial News
Large Cap Stocks
Small-Cap Stocks
Insider Trades
Earnings
Technology
AI News
Personal Finance
ETF News
Crypto News
Dividend News
Latest Rumors
Latest Offerings News
Investment Ideas
Investment Ideas
Stock of the Day
Stock Whisper Index
Analyst Ratings
Analyst Color
Financial Advisors
Government Trades
Trading Ideas
Stock Screener
Markets
Markets
Premarket Movers
After Hours
Options
ETFs
Commodities
Prediction Markets
Private Markets
Bonds
Futures
Forex
Top Stocks
Top Stocks
Apple (AAPL)
Tesla (TSLA)
Amazon (AMZN)
Nvidia (NVDA)
Alphabet (GOOGL)
Meta Platforms (META)
Microsoft (MSFT)
StreetTracks Gold Shares (GLD)
IBIT Bitcoin Trust (IBIT)
Top Value Stocks
Top Momentum Stocks
Top Growth Stocks
Top Quality Stocks
Learn
Learn
Investing Guides
Personal Finance
Mortgages
Best Credit Cards
Best Dividend Stocks
Best Swing Trade Stocks

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Unusual Options Activity Calendar

Stock Split Calendar

Trade Ideas

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Compare Best Stocks

Best Momentum Stocks

Best Quality Stocks

Best Value Stocks

Best Growth Stocks

NOVERIS HEALTH SCIENCES by Noveris Health Sciences Inc. Stock News

MYCOFOTCPK

Trade with Public

Trade with Public

$1.08

At close: May 15, 5:00 PM EST

OverviewNewsShort Interest

Latest NOVERIS HEALTH SCIENCES by Noveris Health Sciences Inc. Stock News | OTC:MYCOF | Benzinga

Get the latest news on NOVERIS HEALTH SCIENCES by Noveris Health Sciences Inc. stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on NOVERIS HEALTH SCIENCES by Noveris Health Sciences Inc. performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, July 31, 2024

EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Javier Hasse

Thursday, February 15, 2024

Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Lara Goldstein

Monday, October 16, 2023

Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
Lara Goldstein

Tuesday, August 15, 2023

Mydecine Releases Q2 2023: Developer Of Smoke Cessation Psilocybin Prodrugs & MDMA Analogs
Lara Goldstein

Wednesday, May 31, 2023

Mydecine's Prospectus Supplement Closing Under Share Subscription And Management Update
Lara Goldstein

Tuesday, May 23, 2023

Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
Lara Goldstein

Wednesday, May 17, 2023

Mydecine's Q1 2023 Reports Shows Decline In Assets And R&D, Increase In Net Loss And Accumulated Deficit
Lara Goldstein

Tuesday, April 25, 2023

New Set Of MDMA Analogs To Hit The Clinic: These Are The Latest Positive Findings
Lara Goldstein

Tuesday, December 20, 2022

Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
Lara Goldstein

Tuesday, December 13, 2022

Psychedelic Company Sale: Mydecine Gets Over $2.5M For Wholly-Owned Tech Subsidiary Business
Lara Goldstein

Tuesday, November 22, 2022

Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Lara Goldstein

Monday, September 26, 2022

Psychedelics Biotechs Clearmind And Mydecine Share Consolidation And Subscription Agreements
Lara Goldstein

Friday, September 23, 2022

Will Cannabis Entrepreneurs Switch To Psychedelics?
Andrew Ward

Tuesday, August 30, 2022

World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them
Lara Goldstein

Friday, August 19, 2022

PRO
Mydecine Innovations Group Announces Private ...
Benzinga Newsdesk

Tuesday, August 16, 2022

Mydecine Innovations Group Reports Q2 Financial Results And Management Updates
Lara Goldstein

Thursday, July 21, 2022

Understanding The Psilocybin Supply Chain: Every Production Method Explained
Natan Ponieman

Tuesday, July 19, 2022

Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change
Lara Goldstein

Friday, June 17, 2022

Government-Funded Smoking Cessation Trial Uses Mydecine's New Psilocybin-Derived MYCO-001, Recently FDA-Approved
Lara Goldstein

Thursday, April 14, 2022

Mydecine Announces 1-for-50 Reverse Stock Split
Fermin Orgambide

Wednesday, April 06, 2022

Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!
Natan Ponieman

Friday, April 01, 2022

Mydecine Reports Financial Results For 2021
Fermin Orgambide

Wednesday, February 09, 2022

Benzinga's Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th
Benzinga Cannabis

Friday, December 17, 2021

Mind Medicine to Study Effect of Time on LSD Microdosing
InvestorBrandNetwork - Sponsored

Tuesday, November 16, 2021

Mydecine: Q3 Financials, Advances Research On Psychedelic Therapies For Mental Health & Addiction Disorders
Jelena Martinovic

Thursday, November 04, 2021

The Legacy Of Dr. Aaron Beck, Father Of Cognitive Therapy, Lives On In Psychedelic Medicine
Natan Ponieman

Wednesday, October 20, 2021

Historic: Federal Agency Awards Grant For Psychedelics Research, First Time In 50 years
Natan Ponieman

Monday, September 27, 2021

Mydecine On Verge Of Finalizing Spin-Out Of Cannabis Subsidiaries, Obtains Shareholder And Court Approval
Jelena Martinovic

Monday, September 13, 2021

Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics
Natan Ponieman

Thursday, August 26, 2021

PharmaDrug Strikes Deal With Johns Hopkins University For A Clinical Trial Into Psychedelic DMT
Natan Ponieman

Monday, August 23, 2021

Psyched: Beckley Psytech Raises $80M, Diamond Therapeutics To Study Psilocybin Microdosing, Mydecine and Johns Hopkins Partner Up
Natan Ponieman

Wednesday, August 18, 2021

Mydecine Innovations Inks Deal With Johns Hopkins University To Undertake Psychedelics Research Into Smoking Cessation
Natan Ponieman

Tuesday, August 03, 2021

Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
Natan Ponieman

Friday, July 02, 2021

Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Natan Ponieman

Wednesday, June 30, 2021

Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
Natan Ponieman

Monday, June 21, 2021

Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
Natan Ponieman

Thursday, June 17, 2021

Mydecine Identifies 4 Psychedelic-Related Drugs to Tackle the Mental Health Crisis
Shashank Jacob

Friday, May 28, 2021

Psyched: Nasdaq Gets Its Third Psychedelics Company, Mynd Goes Public, Delic Buys New Research Facility
Natan Ponieman

Wednesday, May 19, 2021

Mydecine To Spin-Out Its U.S. Cannabis Assets By Mid July
Jelena Martinovic

Friday, May 14, 2021

Psychedelic Therapy Execs On Latest Developments In Space, Remaining Hurdles
Andrew Ward

Tuesday, May 04, 2021

Mydecine Posts $26.9M Net Loss For 2020: What's Ahead For Psychedelic Stock
Natan Ponieman

Tuesday, April 20, 2021

Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week, 4/20/2021
The Cannabis Investor

Tuesday, April 13, 2021

Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week
The Cannabis Investor

Saturday, April 10, 2021

How This Psychedelic Company Could Lead A Turnaround For The Sector
Melanie Schaffer

Wednesday, April 07, 2021

Mydecine Unveils Four Psychedelic Drug Candidates
Natan Ponieman

Monday, March 08, 2021

Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week
The Cannabis Investor

Tuesday, March 02, 2021

Mydecine Exports Psilocybin Mushrooms From Jamaica To Canada — An Industry First
Natan Ponieman

Wednesday, February 17, 2021

Psyched: MindMed Enters Psychedelics 2.0, Mind Cure Raises $18M, Mydecine Raises $13M
Natan Ponieman

Monday, February 08, 2021

Cannabis Stock Gainers And Losers From February 8, 2021
Jose Rodrigo Safdiye
Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week
The Cannabis Investor

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investor Events
Pre-market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2026 Benzinga | All Rights Reserved